Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent to participate in the study~* verified capacity to consent by a doctor not involved in the study~* mild Alzheimer's disease (NINCDS / ADRDA criteria and Mini-Mental State Examination (MMSE) 22-27)~* age (including) from 55 to 90 years~* subjects must be able to meet the requirements described in the study protocol~* outpatient living~* Informant lives with subject in the same household~* Rosen modified Hachinski ischemia score ≤4~* concerning only female patients: postmenopausal~* concerning only male patients: commitment to use a suitable contraceptive~* cerebral imaging study (CT or cMRI), which is consistent with a diagnosis of probable Alzheimer's disease (not older than 3 years)~Exclusion Criteria:~* other neurological and psychiatric diseases explaining cognitive deficits better than an AD diagnosis~* conspicuous MRI / CCT scan explaining the cognitive deficits better than an AD diagnosis~* severe physical, neurological or psychiatric disorders that interfere with the participation in the study~* history of malignant tumors except non- metastasizing basal cell carcinoma of the skin~* history of seizures~* dysphagia leading to the inability to swallow capsules~* untreated severe acute infections with clinical symptoms such as respiratory infections, pneumonia, bronchitis, acute diarrhea, influenza, untreated urinary tract infections~* in the family history, unexplained sudden cases of heart failure before the age of 50 years~* long QT syndrome in the family history~* evidence of QTc prolongation ≥480 ms at screening (Fridericia adjusted QT interval), of arrhythmias especially of severe uncontrolled ventricular arrhythmias or atrial fibrillation in ECG~* not sufficiently treated angina~* heart failure (NYHA III, IV)~* myocardial infarction~* known infection with HBV, HCV and / or HIV~* occurrence of venous thrombosis or embolism~* therapy with antidepressants begun in the last 12 weeks or dose modification of a pre-existing therapy with antidepressants~* antidiabetic treatment begun in the last 12 weeks or dose modification of pre-existing antidiabetic treatment~* long-term use of anti-inflammatory drugs except acetylsalicylic acid for cardiovascular prophylaxis~* current treatment or treatment within the past 12 weeks with HDAC inhibitors (eg valproate)~* taking medication that may increase the dose-dependent side effects myelosuppression or QTc interval prolongation.~These include, but are not limited to:~* Class Ia antiarrhythmic agents such as quinidine, procainamide, disopyramide~* Class III antiarrhythmic drugs such as amiodarone, sotalol, ibutilide~* Class Ic antiarrhythmics such as flecainide, propafenone~* penicillamine~* opioids such as methadone and pyrazolone derivatives such as metamizole and Propyphenazone~* doxorubicin, epirubicin~* macrolides and their analogues such as erythromycin, clarithromycin~* telithromycin~* oxazolidinones such as linezolid~* quinolones such as moxifloxacin, levofloxacin~* fluoxetine, maprotiline~* tricyclic and tetracyclic antidepressants~* chlorpromazine, pimozide, haloperidol, droperidol, ziprasidone and clozapine~* antiemetics~* azole like ketoconazole, fluconazole, voriconazole~* aminocholine such as primaquine~* pentamidine such as quinine, chloroquine~* diaminopyrimidine such as pyrimethamine~* salbutamol and formoterol methotrexate~* azathioprine, cyclosporine Interferon gamma 1b~* alemtuzumab, basiliximab, efalizumab, natalizumab~* sunitinib, nilotinib, lapatinib~* mitoxantrone, Hydroxycarbamide, mercaptopurine~* taking of prescription and non-prescription drugs for cognitive enhancement (except cholinesterase inhibitors and memantine at a stable dose for at least 3 months before baseline)~* therapy with anticoagulants except acetylsalicylic acid~* HbA1c in screening more than 10% above the upper limit of normal~* magnesium, sodium, calcium and potassium levels outside the normal range (at screening and baseline)~* existing anemia with Hb \<11 (at screening and baseline)~* existing thrombocytopenia; platelet ≤150.000 / ul, leukocytes ≤ 3.000 / ul, neutrophils absolutely ≤ 1.500 / ul (at screening and baseline)~* prothrombin or INR ≥ 1.5 above the laboratory limit of normal; PTT ≥ 1.5 x above the laboratory limit of normal (at screening and baseline)~* clinically relevant renal and / or hepatic impairment at screening and baseline (total bilirubin ≥ 1.5 x above the upper limit of the norm and / or GPT, AST ≥ 4x above the upper limit of the norm and / or creatinine ≥ 1.5x above the upper limit of the norm and / or creatinine clearance \<60 ml / min)~* hematuria\> 15 RBCs / mL at screening and baseline~* proteinuria at screening and baseline except in asymptomatic urinary tract infections~* participating in other clinical and therapeutic trials within the last 12 weeks~relevant only for dose confirmation:~* subjects with existing contraindications for performing an MRI if no MRI available from the period of 6 months prior to screening~* cardiac pacemaker~* metal objects in the body, which exclude a 1.5 or 3 T MRI~* claustrophobia

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Investigational drug (Type: EXPERIMENTAL): N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues